Total Payments
$1.5M
2024 Payments
$329,599
Companies
40
Transactions
2,147
Medicare Patients
14,607
Medicare Billing
$990,316
Payment Breakdown by Category
Other$1.2M (76.7%)
Consulting$176,725 (11.6%)
Travel$116,782 (7.7%)
Food & Beverage$45,565 (3.0%)
Research$15,220 (1.0%)
Education$659.93 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.1M | 425 | 74.9% |
| Consulting Fee | $176,725 | 73 | 11.6% |
| Travel and Lodging | $116,782 | 310 | 7.7% |
| Food and Beverage | $45,565 | 1,286 | 3.0% |
| Honoraria | $24,658 | 18 | 1.6% |
| Unspecified | $15,220 | 10 | 1.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,140 | 5 | 0.1% |
| Education | $659.93 | 20 | 0.0% |
Payments by Type
General
$1.5M
2,137 transactions
Research
$15,220
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $364,060 | 400 | $0 (2024) |
| ABBVIE INC. | $326,449 | 511 | $0 (2024) |
| GENZYME CORPORATION | $254,134 | 213 | $0 (2024) |
| PFIZER INC. | $101,247 | 141 | $0 (2024) |
| Dermavant Sciences, Inc. | $99,207 | 151 | $0 (2024) |
| Janssen Biotech, Inc. | $65,247 | 91 | $0 (2024) |
| Incyte Corporation | $64,672 | 67 | $0 (2024) |
| Lilly USA, LLC | $54,486 | 95 | $0 (2024) |
| LEO Pharma Inc. | $38,682 | 122 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $34,465 | 25 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $329,599 | 491 | Dermavant Sciences, Inc. ($59,468) |
| 2023 | $276,170 | 399 | AbbVie Inc. ($55,860) |
| 2022 | $211,338 | 284 | ABBVIE INC. ($59,914) |
| 2021 | $81,779 | 151 | Regeneron Healthcare Solutions, Inc. ($28,883) |
| 2020 | $122,429 | 143 | AbbVie Inc. ($45,182) |
| 2019 | $274,189 | 326 | Regeneron Healthcare Solutions, Inc. ($99,342) |
| 2018 | $183,810 | 233 | Regeneron Healthcare Solutions, Inc. ($68,823) |
| 2017 | $41,683 | 120 | AbbVie, Inc. ($22,873) |
All Payment Transactions
2,147 individual payment records from CMS Open Payments — Page 1 of 86
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | Incyte Corporation | OPZELURA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,600.00 | General |
| Category: Dermatology | ||||||
| 12/20/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $13.64 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $7.04 | General |
| Category: DERMATOLOGY | ||||||
| 12/19/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $2.37 | General |
| Category: DERMATOLOGY | ||||||
| 12/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $2.22 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $1.86 | General |
| Category: DERMATOLOGY | ||||||
| 12/17/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $10.53 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $2.55 | General |
| Category: DERMATOLOGY | ||||||
| 12/16/2024 | LEO Pharma Inc. | ADBRY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,420.00 | General |
| Category: DERMATOLOGY | ||||||
| 12/16/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $22.35 | General |
| Category: DERMATOLOGY | ||||||
| 12/16/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $17.89 | General |
| Category: DERMATOLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $19.40 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $5.78 | General |
| Category: DERMATOLOGY | ||||||
| 12/12/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $3.76 | General |
| Category: DERMATOLOGY | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $14.94 | General |
| Category: Immunology | ||||||
| 12/09/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $80.61 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $15.35 | General |
| Category: Dermatology | ||||||
| 12/09/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $5.06 | General |
| Category: DERMATOLOGY | ||||||
| 12/06/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $23.08 | General |
| Category: DERMATOLOGY | ||||||
| 12/06/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $11.68 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $4.03 | General |
| Category: Dermatology | ||||||
| 12/06/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $3.02 | General |
| Category: Dermatology | ||||||
| 12/05/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $12.84 | General |
| 12/04/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $124.99 | General |
| Category: Dermatology | ||||||
| 12/03/2024 | Medimetriks Pharmaceuticals, Inc. | Neuac (Drug), Clindacin ETZ | Food and Beverage | In-kind items and services | $37.32 | General |
| Category: Dermatology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $9,236 | 5 |
| PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED, SINGLE-ARM, PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB | Eli Lilly and Company | $5,152 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA | Eli Lilly and Company | $727.80 | 3 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | Eli Lilly and Company | $104.58 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 3,580 | 6,877 | $676,838 | $247,261 |
| 2022 | 20 | 3,688 | 7,018 | $679,629 | $255,205 |
| 2021 | 21 | 3,754 | 7,519 | $686,311 | $254,504 |
| 2020 | 22 | 3,585 | 6,994 | $606,521 | $233,347 |
Total Patients
14,607
Total Services
28,408
Medicare Billing
$990,316
Procedure Codes
84
All Medicare Procedures & Services
84 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 1,214 | 1,827 | $283,163 | $101,992 | 36.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 452 | 527 | $91,745 | $33,859 | 36.9% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 631 | 889 | $99,026 | $31,910 | 32.2% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 238 | 267 | $50,738 | $19,989 | 39.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 109 | 149 | $32,986 | $12,688 | 38.5% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 449 | 2,624 | $28,339 | $12,255 | 43.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 96 | 96 | $18,451 | $7,130 | 38.6% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 45 | 50 | $15,095 | $5,315 | 35.2% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 95 | 132 | $11,732 | $4,879 | 41.6% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 23 | 33 | $9,211 | $3,574 | 38.8% |
| 96567 | Application of light to destroy precancer skin growth | Office | 2023 | 26 | 31 | $7,349 | $2,656 | 36.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 51 | 52 | $5,004 | $1,959 | 39.2% |
| 17272 | Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | Office | 2023 | 14 | 15 | $4,798 | $1,881 | 39.2% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 18 | 19 | $4,149 | $1,673 | 40.3% |
| 69100 | Biopsy of ear | Office | 2023 | 24 | 26 | $4,356 | $1,468 | 33.7% |
| 11301 | Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | Office | 2023 | 13 | 14 | $2,938 | $1,234 | 42.0% |
| 11300 | Shaving of skin growth of body, arms, or legs, 0.5 cm or less | Office | 2023 | 18 | 18 | $3,108 | $1,134 | 36.5% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 17 | 26 | $2,478 | $922.17 | 37.2% |
| 11200 | Removal of skin tag, 1-15 skin tags | Office | 2023 | 12 | 12 | $1,824 | $628.86 | 34.5% |
| Q0112 | All potassium hydroxide (koh) preparations | Office | 2023 | 12 | 15 | $75.00 | $73.50 | 98.0% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 23 | 55 | $275.00 | $39.28 | 14.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 1,178 | 1,740 | $270,052 | $100,372 | 37.2% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 510 | 583 | $101,494 | $38,968 | 38.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 682 | 936 | $104,261 | $34,400 | 33.0% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 225 | 263 | $49,978 | $19,767 | 39.6% |
About Dr. Rocco Serrao, MD
Dr. Rocco Serrao, MD is a Dermatology healthcare provider based in Dayton, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/18/2008. The National Provider Identifier (NPI) number assigned to this provider is 1124274477.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rocco Serrao, MD has received a total of $1.5M in payments from pharmaceutical and medical device companies, with $329,599 received in 2024. These payments were reported across 2,147 transactions from 40 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.1M).
As a Medicare-enrolled provider, Serrao has provided services to 14,607 Medicare beneficiaries, totaling 28,408 services with total Medicare billing of $990,316. Data is available for 4 years (2020–2023), covering 84 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Dayton, OH
- Active Since 08/18/2008
- Last Updated 08/03/2016
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1124274477
Products in Payments
- DUPIXENT (Biological) $398,592
- DUPIXENT (Drug) $147,848
- SKYRIZI (Biological) $118,304
- TREMFYA (Drug) $99,405
- RINVOQ (Biological) $83,845
- VTAMA (Drug) $73,935
- DUPIXENT DUPILUMAB INJECTION (Biological) $68,815
- OPZELURA (Drug) $57,762
- Humira (Biological) $54,514
- EUCRISA (Drug) $48,909
- OLUMIANT (Drug) $32,466
- ADBRY (Biological) $31,873
- CIBINQO (Drug) $30,828
- TAPINAROF (Drug) $25,273
- Skyrizi (Biological) $21,683
- Zoryve (Drug) $16,551
- HUMIRA (Biological) $15,128
- TALTZ (Drug) $14,906
- AMZEEQ (Drug) $14,315
- Olumiant (Drug) $13,750
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Dayton
Dr. Matthew Bakos, M.d, M.D
Dermatology — Payments: $146,885
Dermatology $146,885
Jeffrey Travers, Md, Ph.d, MD, PH.D
Dermatology — Payments: $108,675
Dermatology $108,675
Shannon Verma, M.d, M.D
Dermatology — Payments: $12,575
Dermatology $12,575
Dr. Brian Russ, M.d, M.D
Dermatology — Payments: $11,676
Dermatology $11,676
Bruce Brumfiel, M.d, M.D
Dermatology — Payments: $11,071
Dermatology $11,071
Suzanne Dundon, M.d, M.D
Dermatology — Payments: $5,054
Dermatology $5,054